Glenmark, Helsinn enter into licensing agreement to launch AKYNZEO in India, Nepal

04 Apr 2018 Evaluate

Glenmark Pharmaceuticals and Helsinn Group (Helsinn) have entered into an exclusive licensing agreement to introduce AKYNZEO in India and Nepal.

AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing agreement with Glenmark for AKYNZEO represents Helsinn’s first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal.

Glenmark has received marketing approval for AKYNZEO from the Central Drugs Standard Control Organization (CDSCO).

Glenmark’s current portfolio consists of 131 products authorized for distribution in the US marketplace and 63 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

1962.20 -3.55 (-0.18%)
08-Dec-2025 11:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.30
Dr. Reddys Lab 1276.15
Cipla 1511.75
Zydus Lifesciences 932.75
Lupin 2089.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×